Target intelligence / Profile preview

Arginine deiminase (ADI)

Target: ADI
Molecular classification: Enzyme, Hydrolase

Overview

Arginine deiminase (ADI) is an enzyme that catalyzes the hydrolysis of L-arginine to L-citrulline and ammonia. It plays a key role in arginine catabolism in bacteria and has been studied as an anti-cancer agent due to its ability to deplete arginine in tumors that cannot synthesize it.

Other names: Arginine dihydrolaseCitrulline iminaseL-arginine deiminaseL-arginine iminohydrolase

Mechanism of action

Depletes extracellular arginine, depriving argininosuccinate synthetase-deficient tumors of this essential amino acid.

Biological functions

Arginine and proline metabolismEnergy generationpH regulation

Disease associations

CancerInfection

Safety considerations

Potential for immune response against the enzyme

Biomarkers

Argininosuccinate synthetase deficiencyArgininosuccinate lyase deficiency

Beyond the preview

Go deeper on Arginine deiminase (ADI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arginine deiminase (ADI).

Explore the full profile